08:37 AM EDT, 06/03/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) presented updated clinical results showing "significant" survival benefit in the Phase 2b Study of bizaxofusp (MDNA55) in patients with recurrent gliobastoma (rGBM) at the Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 1.

The data was compared with a matched external control arm, the company said.

"Bizaxofusp represents a promising novel approach for targeted delivery of a potent therapeutic payload in rGBM, a uniformly fatal form of brain cancer that does not have an approved standard of care," said Dr. Fahar Merchant, president and CEO of Medicenna. "These updated Phase 2b analysis reflect the planned design of a Phase 3 registration trial where patients with unresectable rGBM will be treated with bizaxofusp at the high dose."

Medicenna is pursuing partnership opportunities, and will seek Breakthrough Therapy Designation, and secure alignment with the European Medicines Agency for the Phase 3 trial design.